Consumption of nattokinase is associated with reduced blood pressure and von willebrand factor, a cardiovascular risk marker: Results from a randomized, double-blind, placebo-controlled, multicenter north american clinical trial

Integrated Blood Pressure Control

Volumn 9, Issue , 2016, Pages 95-104

  Jensen, Gitte S ^a   Lenninger, Miki ^a   Ero, Michael P ^b   Benson, Kathleen F ^a  

^a NIS Labs   (United States)

^b Machaon Diagnostics Inc   (United States)

Author keywords

Diastolic blood pressure; Plasma renin activity; Subtilisin NAT; Systolic blood pressure; von Willebrand factor

Indexed keywords

NATTOKINASE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THERAPY EFFECT;

EID: 84992401832     PISSN: None     EISSN: 11787104     Source Type: Journal    
DOI: 10.2147/IBPC.S99553     Document Type: Article

References (45)

1. Kim MJ, Lim NK, Choi SJ, Park HY. Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. Hypertens Res. 2015; 38 (11): 783–789.
2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21 (11): 1983–1992.
3. Mancia G, Fagard R, Narkiewicz K, et al; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014; 23 (1): 3–16.
4. U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007; 147: 783.
5. Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015; 162 (3): 192–204.
6. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011; 343: d4891.
7. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012; 379 (9819): 905–914.
8. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008; 52 (1): 1–9.
9. Yoon S, Ostchega Y, Louis T. Recent Trends in the Prevalence of High Blood Pressure and Its Treatment and Control, 1999–2008. Hyattsville, MD: National Center for Health Statistics; 2010. [NCHS data brief, no 48].
10. Fryar CD, Hirsch R, Eberhardt MS, et al. Hypertension, High Serum Total Cholesterol, and Diabetes: Racial and Ethnic Prevalence Differences in U.S. Adults, 1999–2006. Hyattsville, MD: National Center for Health Statistics; 2010. [NCHS data brief, no 36].
11. Gillespie C, Kuklina EV, Briss PA, Blair NA, Hong Y. Vital signs: prevalence, treatment, and control of hypertension-United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011; 60 (04): 103–108.
12. Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez B. Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf. 2015; 6 (4): 166–176.
13. Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. BMC Complement Altern Med. 2012; 12: 26.
14. Yarnell EL. Botanical medicines used for kidney disease in the United States. Iran J Kidney Dis. 2012; 6 (6): 407–418.
15. Kaur N, Chugh V, Gupta AK. Essential fatty acids as functional components of foods-a review. J Food Sci Technol. 2014; 51 (10): 2289–2303.
16. Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015; 19 (3): 441–445.
17. Ellulu MS, Khaza’ai H, Abed Y, Rahmat A, Ismail P, Ranneh Y. Role of fish oil in human health and possible mechanism to reduce the inflammation. Inflammopharmacology. 2015; 23 (2–3): 79–89.
18. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995; 25: 155–161.
19. Altman R, Scazziota A, Rouvier J, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol. 1996; 19 (7): 549–554.
20. Yanagisawa Y, Chatake T, Chiba-Kamoshida K, et al. Purification, crystallization and preliminary X-ray diffraction experiment of nattokinase from Bacillus subtilis natto. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010; 66 (12): 1670–1673.
21. Fujita M, Nomura K, Hong K, Ito Y, Asada A, Nishimuro S. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun. 1993; 197 (3): 1340–1347.
22. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987; 43 (10): 1110–1111.
23. Xu J, Du M, Yang X, Chen Q, Chen H, Lin DH. Thrombolytic effects in vivo of nattokinase in a carrageenan-induced rat model of thrombosis. Acta Haematol. 2014; 132 (2): 247–253.
24. Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 2015; 5: 11601.
25. Jang JY, Kim TS, Cai J, et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Lab Anim Res. 2013; 29 (4): 221–225.
26. Berkner KL. Vitamin K-dependent carboxylation. Vitam Horm. 2008; 78: 131–156.
27. Fujita M, Hong K, Ito Y, et al. Transport of nattokinase across the rat intestinal tract. Biol Pharm Bull. 1995; 18 (9): 1194–1196.
28. Ero MP, Ng CM, Mihailovski T, Harvey NR, Lewis BH. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Altern Ther Health Med. 2013; 19 (3): 16–19.
29. Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M. Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct. 2012; 3 (6): 674–678.
30. Kim YK, Kim SM, Kim JY, Kwon O. The culture filtrates from Bacillus subtilis natto lowers blood pressure via renin–angiotensin system in spontaneously hypertensive rats fed with a high-cholesterol diet. J Korean Soc Appl Bio Chem. 2011; 54 (6): 959–965.
31. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol. 1990; 84 (3): 139–143.
32. Fujita M, Hong K, Ito Y, Fujii R, Kariya K, Nishimuro S. Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull. 1995; 18 (10): 1387–1391.
33. Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized controlled trial. Hypertens Res. 2008; 31: 1583–1588.
34. Ueda T, Kawakami R, Nishida T, et al. Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin–angiotensin system inhibitors. Circ J. 2015; 79 (6): 1307–13014.
35. Haymond S, Clarke NJ, Reitz RE, McPhaul MJ, Wu Z. Plasma renin activity: the importance of correct sample type. Clin Chem. 2016; 62 (2): 408–409.
36. Baker HN, Murphy R, Lopez E, Garcia C. Conversion of a capture ELISA to a Luminex xMAP assay using a multiplex antibody screening method. J Vis Exp. 2012; 65: 4084.
37. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001; 37: 1199–1208.
38. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V. The determinants of plasma-renin activity in essential hypertension. Ann Intern Med. 1978; 88: 746–752.
39. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986; 105 (5): 649–654.
40. Kim JM, Kim TH, Lee HH, Lee SH, Wang T. Postmenopausal hypertension and sodium sensitivity. J Menopausal Med. 2014; 20 (1): 1–6.
41. Felmeden DC, Lip GYH. The renin–angiotensin–aldosterone system and f ibrinolysis. J Renin Angiotensin Aldosterone Syst. 2000; 1 (3): 240–244.
42. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006; 37 (11): 2672–2677.
43. Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010; 41 (10): 2151–2156.
44. Jenkins PV, O’Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion. 2006; 46: 1836–1844.
45. Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Novel aspects of fibrin (ogen) fragments during inflammation. Mol Med. 2011; 17 (5–6): 568–573.